Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 16 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Apr 2024 According to a Revance Therapeutics media release, data assessing patient-desired retreatment intervals and examining the influence of the formulation of DAXXIFY on clinical performance, will be presented at the annual meeting of American Academy of Neurology (AAN), taking place April 13-18, 2024, in Denver, Colorado.
02 Feb 2024 Results published in a Revance Therapeutics media release.
02 Feb 2024 According to a Revance Therapeutics media release, publication of results from the ASPEN-1 Pivotal Phase 3 study in Neurology, the medical journal of the American Academy of Neurology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com